Search

Your search keyword '"Chang, Kaitao"' showing total 14 results
Start Over Author "Chang, Kaitao"
14 results on '"Chang, Kaitao"'

2. Pipeline Embolization Device for Small and Medium Vertebral Artery Aneurysms: A Multicenter Study

Author

Zhang, Hongyun, primary, Zhang, Hongqi, additional, Liu, Jianmin, additional, Song, Donglei, additional, Zhao, Yuanli, additional, Guan, Sheng, additional, Maimaitili, Aisha, additional, Wang, Yunyan, additional, Feng, Wenfeng, additional, Wang, Yang, additional, Wan, Jieqing, additional, Mao, Guohua, additional, Shi, Huaizhang, additional, Luo, Bin, additional, Shao, Qiuji, additional, Chang, Kaitao, additional, Zhang, Qianqian, additional, He, Yingkun, additional, Zhang, Peng, additional, Yang, Xinjian, additional, Li, Li, additional, and Li, Tian xiao, additional

Published
2022
Full Text
View/download PDF

6. Small and Medium-Sized Aneurysm Outcomes Following Intracranial Aneurysm Treatment Using the Pipeline Embolization Device: A Subgroup Analysis of the PLUS Registry

Author

Zhang, Hongyun, primary, Li, Li, additional, Zhang, Hongqi, additional, Liu, Jianmin, additional, Song, Donglei, additional, Zhao, Yuanli, additional, Guan, Sheng, additional, Maimaitili, Aisha, additional, Wang, Yunyan, additional, Feng, Wenfeng, additional, Wang, Yang, additional, Wan, Jieqing, additional, Mao, Guohua, additional, Shi, Huaizhang, additional, Luo, Bin, additional, Shao, Qiuji, additional, Chang, Kaitao, additional, Zhang, Qianqian, additional, He, Yingkun, additional, Zhang, Peng, additional, Yang, Xinjian, additional, and Li, Tian xiao, additional

Published
2022
Full Text
View/download PDF

8. Endovascular Aneurysm Treatment with the Numen Coil Embolization System: A Prospective Randomized Controlled Open-Label Multicenter Noninferiority Trial in China

Author

Rui Zhao, Guoli Duan, Pengfei Yang, Tianxiao Li, Sheng Guan, Hua Yang, Zhenwei Zhao, Xingen Zhu, Guobiao Liang, Xin Wu, Bing Leng, Yang Wang, Yina Wu, Qiao Zuo, Lei Zhang, ZiFu Li, Yu Zhou, Kaijun Zhao, Dongwei Dai, Yibin Fang, Qiang Li, Qinghai Huang, Bo Hong, Yi Xu, Jianmin Liu, Zhang Kaixia, Chen Gong, Ann Qingzhu, Zheng Yongtao, He Yingkun, Bai Weixing, Kang Xiaoyu, Wang Ning, Guan Min, Xu Bin, Duan Guangming, Li Li, Zhu Liangfu, Zhou Zhilong, Shao Qiuji, Chang Kaitao, Wu Liheng, Li Qiang, Gu Jianjun, Zhang Kun, Wang Yongfeng, Zhao Zhiyu, Chen Zhen, Xu Haowen, Wang Linyu, Guo Xinbin, Liu Chao, Fang Feng, Liu Zining, Guo Yuanyuan, Chen Hu, Yan Zhongjun, Fang Wei, Lu Wenyan, Li Jiang, Deng Jianping, Li Zhihong, Gao Xu, Wang Xiaogang, Dong Yushu, Li Chuangzhong, Liu Song, Teng Lu, Yuan Yuan, Shang Minghua, Zhang Zaiqiang, Wang Jing, Sang Guifeng, Cheng Jiyong, Zhang Zhen, Zhou Xiaobing, Chen Yan, Lai Lingfeng, Dong Youqing, Mao Guohua, Zhu Jianming, Lai Xianliang, Gao Ziyun, Song Shuxin, Ye Minhua, Fan Yijin, Xiang Xin, Peng Han, Yan Jian, and Fang Wenting

Subjects
Blood Vessel Prosthesis Implantation, Treatment Outcome, Endovascular Procedures, Humans, Surgery, Intracranial Aneurysm, Neurology (clinical), Prospective Studies, Embolization, Therapeutic, Aortic Aneurysm, Abdominal, Follow-Up Studies
Abstract

We investigated the safety and efficacy of the Numen coil compared with the Axium coil in the treatment of intracranial aneurysms.Because CATCH (Coil Application Trial in China) is a prospective randomized controlled open-label noninferiority trial conducted in 10 centers across China, patients who fulfilled the inclusion and exclusion criteria were randomized 1:1 to either a test group (Numen) or a control group (Axium). The primary outcome was based on successful aneurysm occlusion at 6 months follow-up, whereas secondary outcomes included technical success, the recanalization and retreatment rates, and the rate of serious adverse events (SAEs) at 6 months and 12 months follow-up.Between August 2017 and December 2019, 350 patients presenting with 350 aneurysms were enrolled and randomized. Per-protocol analysis showed that the successful aneurysm occlusion rate at 6 months was 91.18% for the test group compared with 91.85% in the control group, with a difference of -0.68% (P = 0.8419), and the overall mortality during the 30-day follow-up period was 1.19% and 1.81% in the test and control group, respectively, showing no significant difference between the 2 groups (P = 0.6837), whereas the SAE incidence during the 12-month follow-up period was 12.50% and 17.47% in the test and control groups, respectively, which was not statistically significant (P = 0.2222).This trial showed that the Numen coil was noninferior to the Axium coil in terms of intracranial aneurysm embolization and can be considered as a safe and effective coil for treating patients with intracranial aneurysm in clinical practice.

Published
2021

13. Intracranial aneurysms managed by parent artery reconstruction using Tubridge: Study protocol for a prospective, multicenter, post-market clinical trial.

Author

Wu, Qiaowei, Li, Li, Shao, Qiuji, Xu, Tianming, Chang, Kaitao, Li, Tianxiao, and He, Yingkun

Subjects
INTRACRANIAL aneurysms, RESEARCH protocols, CLINICAL trials, MORTALITY, LONGITUDINAL method
Abstract

Background: As a new endovascular reconstruction technique, flow diverter (FD) shows excellent efficacy and safety for treatment of intracranial aneurysms. In a previous multicenter, randomized, controlled, pre-market study, Tubridge FD showed remarkably higher complete occlusion rate compared with traditional stent-assisted coiling. However, a nonsignificant higher complication rate in the Tubridge group was noted. Considering the learning curve, the safety, and long-term outcomes of Tubridge FD should be verified in new prospective, real world, multicenter, post-market trials. Methods: This study is a prospective, multicenter, single-arm, post-market clinical trial that evaluates the safety and efficacy of Tubridge in the treatment of patients with intracranial aneurysms by reconstructing parent artery. We expect 200 participants who meet the inclusion and exclusion criteria to be included. Clinical information and angiographic results (Raymond–Roy grading scale, RRGS) will be recorded objectively. The primary endpoint will be the complete occlusion rate of the target aneurysm (RRGS 1) at 12-month follow-up. Secondary endpoints will include the adequate occlusion rate (RRGS 1 & 2) and the rate of major in-stent stenosis (>50%) at 12-month follow-up, technique success rate, changes of modified Rankin Scale before and after the procedure, the rate of aneurysm related disability, neurological mortality, and all-cause mortality within follow-up period. Discussion: This post-market, prospective trial may offer more information on the safety and long-term outcomes of Tubridge FD. When the study is complete, the results may provide us a new strategy for the treatment of intracranial aneurysms. Trial registration: WHO-Chinese Clinical Trial Registry: ChiCTR2000032282. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

14. Prophylactic administration of tirofiban for preventing thromboembolic events in flow diversion treatment of intracranial aneurysms

Author

Wu, Qiaowei, Shao, Qiuji, Li, Li, Liang, Xiaodong, Chang, Kaitao, Li, Tianxiao, and He, Yingkun

Abstract

BackgroundFlow diverter (FD) is widely used in the treatment of intracranial aneurysms. However, thromboembolic events (TEs) continue to be the major complications during the periprocedural phase. To evaluate the safety and efficacy of the prophylactic use of tirofiban, combined with the conventional dual antiplatelet therapy (DAT), as a new antiplatelet protocol in patients with intracranial aneurysms treated with FDs.MethodsAt least 3–5 days before the procedure, daily DAT were administrated to the patients. Tirofiban was administered as an intravenous bolus (5 µg/kg) over a 3 min period during or immediately after FD deployment, followed by a 0.05 µg/kg/min maintenance infusion for 24–48 hours. Periprocedural TEs and hemorrhagic events (HEs) were recorded.ResultsA total of 331 patients were included, including 229 (69.2%) who received tirofiban administration (tirofiban group) and 102 (30.8%) who received only DAT (non-tirofiban group). Periprocedural TEs occurred in 12 (3.6%) patients, including eight (7.8%) in the non-tirofiban group and four (1.7%) in the tirofiban group. In multivariate analysis, patients receiving tirofiban administration had significantly lower TEs as compared with those who received only DAT (P=0.004). Balloon angioplasty and longer procedure time (>137 min) were also risk factors for TEs. Also, no increase was observed in the rate of HEs related to tirofiban administration.ConclusionsThe current study suggested that prophylactic administration of tirofiban combined with conventional oral DAT seems safe and efficient for preventing TEs during FD treatment of unruptured intracranial aneurysms. Balloon angioplasty and prolonged procedure are associated with a high risk of TEs.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results